Quantcast

Latest Monoclonal antibodies Stories

2014-07-15 08:28:23

MONROVIA, Calif., July 15, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced the appointment of Kurt Gustafson to its board of directors. Mr. Gustafson will also serve as chair of Xencor's audit committee and as a member of the compensation committee. Xencor also announced the promotion of John R....

2014-07-13 23:01:22

The increasing number of research activities, coupled with the introduction of advanced technologies in chromatography instruments and consumables, will drive the growth of chromatography systems market. http://www.micromarketmonitor.com/market/north-america-chromatography-systems-3162983548.html (PRWEB) July 13, 2014 Chromatography system is a physical method of separation of biological components from various types of biological samples such as air and water. Chromatography systems...

2014-07-10 12:30:51

ST. PETERSBURG, Russia, July 10, 2014 /PRNewswire/ -- On July 9 Prime Minister of the Russian Federation Dmitry Medvedev, presented Russia's first national "Industry" award to a biopharmaceutical company BIOCAD [http://biocad.ru/en ]. The Company is developing a unique project called MabNext [http://biocad.ru/en/science ]. Within the scope of MabNext project BIOCAD develops a number of innovative drugs based on monoclonal antibodies for treatment of cancer and autoimmune...

2014-07-07 16:02:23

European League Against Rheumatism Low dosing of infliximab does not appear to alter treatment response or adherence Data presented today at the European League Against Rheumatism Annual Congress (EULAR 2014) showed that a significant number of patients with psoriatic arthritis (PsA) were not receiving doses of the tumour necrosis factor-alpha (TNFα) inhibitor adalimumab necessary to achieve optimal clinical benefit. Further data revealed that, in the case of the TNFα inhibitor...

First Antibodies To Treat Cancer In Dogs Developed
2014-07-07 03:10:21

University of Veterinary Medicine Vienna Nearly every second dog develops cancer from the age of ten years onward. A few therapies derived from human medicine are available for dogs. A very successful form of therapy by which antibodies inhibit tumor growth has not been available for animals so far. Scientists at the inter-university Messerli Research Institute of the Vetmeduni Vienna, the Medical University of Vienna, and the University of Vienna have developed, for the first time,...

2014-07-03 23:03:22

High demand for chromatography reagents in the pharmaceutical industry and innovation in chromatography reagents market will propel the global size exclusion chromatography reagents market. http://www.micromarketmonitor.com/market-report/global-size-exclusion-chromatography-reagents-reports-4179419567.html (PRWEB) July 03, 2014 The global size exclusion chromatography reagents market was $812 million in 2013, and is expected to reach $1302 million by 2018, at a CAGR of 9.9%. Rise in...

2014-07-03 08:23:49

MUMBAI,India, July 3, 2014 /PRNewswire/ -- - GBR 830 is an antagonistic monoclonal antibody with first in class potential for the treatment of autoimmune diseases targeting OX40, a co-stimulatory receptor on T cells - The antibody has successfully completed the Phase I enabling preclinical development program and a Phase I clinical trial application has been filed with The Netherlands authorities -...

2014-07-01 12:28:27

COLLEGE PARK, Md., July 1, 2014 /PRNewswire-USNewswire/ --The University of Maryland (UMD) Fischell Department of Bioengineering and the Maryland Center for Excellence in Regulatory Science (M-CERSI) have partnered with the Global Biological Standards Institute (GBSI) to launch the Collaboration to Advance Antibody Standards. This collaboration between the Fischell Department of Bioengineering and GBSI will allow for assessment of the current antibody standards landscape and...

2014-07-01 08:30:44

SAN DIEGO, July 1, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced that it has received two NIH small business grants which will fund the development of bispecific antibodies for two of its anti-bacterial immunotherapies. Sorrento's highly diverse, fully human G-MAB(®) library and proprietary antibody conjugation technology platforms have...

2014-07-01 08:29:55

Breakthrough Designation Reinforces Significant Unmet Need in the Treatment of This Highly Aggressive Cancer THOUSAND OAKS, Calif., July 1, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to investigational bispecific T cell engager (BiTE(®)) antibody blinatumomab, for adults with Philadelphia-negative (Ph-) relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL), a rapidly...


Word of the Day
Cthulhu
  • A gigantic fictional humanoid alien god being described with a head resembling an octopus and dragon wings and claws, around whom an insane cult developed.
  • Pertaining to the mythos of Cthulhu and additional otherworldly beings created by H. P. Lovecraft or inspired by his writings and imitators.
This word was invented in 1926 by H.P. Lovecraft for his short story, 'The Call of Cthulhu.' 'Cthulhu' may be based on the word 'chthonic,' which in Greek mythology refers to the underworld.
Related